Is there a link between very early changes of primary and secondary lymphoid organs in <sup>18</sup>F-FDG-PET/MRI and treatment response to checkpoint inhibitor therapy?

Seith, Ferdinand; Forschner, Andrea; Weide, Benjamin; Gückel, Brigitte; Schwartz, Martin; Schwenck, Johannes; Othman, Ahmed E; Fenchel, Matthias; Garbe, Claus; Nikolaou, Konstantin; Schwenzer, Nina; la Fougère, Christian; Pfannenberg, Christina

Is there a link between very early changes of primary and secondary lymphoid organs in ¹⁸F-FDG-PET/MRI and treatment response to checkpoint inhibitor therapy?

Seith, Ferdinand; Forschner, Andrea; Weide, Benjamin; Gückel, Brigitte; Schwartz, Martin; Schwenck, Johannes; Othman, Ahmed E; Fenchel, Matthias; Garbe, Claus; Nikolaou, Konstantin; Schwenzer, Nina; la Fougère, Christian; Pfannenberg, Christina.

Afiliação

Seith F; Diagnostic and Interventional Radiology, Eberhard Karls University Tübingen, Tübingen, Germany ferdinand.seith@med.uni-tuebingen.de.
Forschner A; Dermatology, Eberhard Karls University Tübingen, Tübingen, Baden-Württemberg, Germany.
Weide B; Dermatology, Eberhard Karls University Tübingen, Tübingen, Baden-Württemberg, Germany.
Gückel B; Diagnostic and Interventional Radiology, Eberhard Karls University Tübingen, Tübingen, Germany ferdinand.seith@med.uni-tuebingen.de.
Schwartz M; Section on Experimental Radiology, Eberhard Karls University Tübingen, Tubingen, Germany.
Schwenck J; Nuclear Medicine and Clinical Molecular Imaging, Eberhard Karls University Tübingen, Tubingen, Baden-Württemberg, Germany.
Othman AE; Preclinical Imaging and Radiopharmacy, Werner Siemens Imaging Center, Tübingen, Baden-Württemberg, Germany.
Fenchel M; Cluster of Excellence iFIT (EXC 2180) "Image-Guided and Functionally Instructed Tumor Therapies", Eberhard Karls University, 72076 Tübingen, Germany
Garbe C; Diagnostic and Interventional Radiology, Eberhard Karls University Tübingen, Tübingen, Germany ferdinand.seith@med.uni-tuebingen.de.
Nikolaou K; Diagnostic Imaging, Magnetic Resonance, Siemens Healthcare GmbH, Erlangen, Bayern, Germany.
Schwenzer N; Dermatology, Eberhard Karls University Tübingen, Tübingen, Baden-Württemberg, Germany.
la Fougère C; Diagnostic and Interventional Radiology, Eberhard Karls University Tübingen, Tübingen, Germany ferdinand.seith@med.uni-tuebingen.de.
Pfannenberg C; Cluster of Excellence iFIT (EXC 2180) "Image-Guided and Functionally Instructed Tumor Therapies", Eberhard Karls University, 72076 Tübingen, Germany

J Immunother Cancer ; 8(2)2020 08.

Article em En | MEDLINE | ID: mdl-32753543

Assuntos

Fluordesoxiglucose F18/uso terapêutico; Inibidores de Checkpoint Imunológico/uso terapêutico; Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada/métodos; Feminino; Fluordesoxiglucose F18/farmacologia; Humanos; Inibidores de Checkpoint Imunológico/farmacologia; Masculino; Estudos Prospectivos

Palavras-chave

CTLA-4 antigen; melanoma; programmed cell death 1 receptor

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fluordesoxiglucose F18 / Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada / Inibidores de Checkpoint Imunológico Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male Idioma: En Revista: J Immunother Cancer Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google